Black checkmark with a sparkle and a curved line underneath on a white background.
Company

IMMUCELL CORP /DE/

Ticker
ICCC
Sector
Industry
Report date
November 12, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight ImmuCell's sales growth, earnings improvements, and operational updates in 2026, alongside stock price volatility.

Recent developments:
  • ImmuCell reported preliminary Q2 2026 sales of $7 million with a 20% rise for six-month sales in preliminary results [N4].
  • Q2 2026 earnings call highlighted year-over-year earnings and sales growth, though the stock price fell 8.8% despite these improvements [N1][N2][N3].
  • Q1 2026 earnings rose year-over-year with sales climbing on strong demand, driven by Tri-Shield sales [N5][N7].
  • The company is repurposing a manufacturing facility previously used for Re-Tain® to produce First Defense® products [S2].
  • Net income of approximately $0.95 million and EPS of $0.10 were reported for Q3 2026, reflecting profitability [S2].
Overview

ImmuCell Corporation operates in the animal health sector, specializing in products aimed at cattle health management. The company’s product portfolio includes First Defense® and Tri-Shield, which contribute to its revenue growth. ImmuCell maintains a strong liquidity position with cash and equivalents of nearly $7.9 million and a current ratio above 4 as of Q3 2026. The company has reported net income and positive earnings per share in recent quarters, reflecting operational profitability. Manufacturing facilities are being repurposed to support product lines, indicating ongoing operational adjustments. ImmuCell’s shares trade on Nasdaq under the ticker ICCC, with approximately 9 million shares outstanding. The company has multiple debt instruments and lease agreements with regional financial institutions. Recent news coverage emphasizes sales growth and earnings improvements, although stock price movements have shown some volatility.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. ImmuCell Corporation is a Delaware-based company trading on Nasdaq under ICCC. As of September 30, 2026, the company reported net income of approximately $0.95 million and earnings per share of $0.10. Cash and cash equivalents stood at about $7.9 million, with a strong liquidity position reflected in a current ratio of 4.61. The company’s revenue for Q2 2025 was approximately $6.44 million. Recent news highlights include year-over-year sales growth and earnings improvements in 2026, with Q2 sales reaching $7 million and a 20% increase in six-month sales. The company focuses on cattle health products such as First Defense® and Tri-Shield, with ongoing operational adjustments including refitting manufacturing facilities. Debt and lease arrangements are in place with regional banks. The stock experienced price volatility despite positive earnings trends in recent quarters.

Scenarios for ICCC

Bull case model:

ImmuCell has demonstrated consistent sales growth and improving profitability, supported by strong demand for its cattle health products. The company’s liquidity position and manageable debt levels provide financial flexibility. Operational initiatives such as repurposing manufacturing facilities for key product lines indicate strategic focus on core offerings. Continued execution on sales growth and margin improvement could enhance the company’s market position within its niche. Positive earnings trends and product acceptance in the market underpin potential for sustained operational performance.

Bear case model:

Despite earnings and sales growth, ImmuCell’s stock price has experienced declines, reflecting market volatility or investor concerns. The company operates in a competitive animal health market with potential regulatory and operational risks. Repurposing manufacturing facilities may involve execution risks and capital expenditures. Dependence on a limited product portfolio and regional financial institutions for debt financing could constrain growth. Market perception and external factors such as commodity prices and cattle industry dynamics may impact business performance.

Moat:

ImmuCell’s moat is derived from its specialized focus on cattle health products, including proprietary formulations like First Defense® and Tri-Shield. The company’s niche positioning in animal health, combined with established manufacturing capabilities and regulatory approvals, supports its competitive advantage. Long-term relationships with regional financial institutions and a history of product development and commercialization contribute to operational stability. However, the moat is moderate given the competitive nature of the animal health market and the company’s relatively small scale compared to larger industry players.

Risks overview
Risks summary
The primary risks for ImmuCell include competitive pressures in the animal health market, regulatory compliance challenges, and operational execution risks related to manufacturing adjustments.
Risks details:

• Market Competition: ImmuCell faces competition from larger animal health companies with broader product portfolios and greater resources.
• Regulatory Risks: The company’s products are subject to regulatory approvals and compliance, which can affect product availability and costs.
• Operational Execution: Repurposing manufacturing facilities and scaling production involve execution risks and potential delays.
• Financial Risks: Dependence on regional banks for debt financing and lease obligations may limit financial flexibility.
• Market Volatility: Stock price volatility despite positive earnings indicates sensitivity to market sentiment and external factors affecting the cattle industry.

FINAL FORECAST FOR ICCC

Final take one line
ImmuCell exhibits strong business model visibility with detailed financials and consistent sales growth in its niche cattle health market.
Final take 12 to 24 month view

Business trends: Continued sales growth and earnings improvements driven by core cattle health products and operational adjustments.
Execution milestones: Repurposing manufacturing facilities and maintaining strong liquidity and profitability metrics.
Key risks: Market competition, regulatory compliance, operational execution challenges, and stock price volatility.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • ImmuCell Corporation is a Delaware corporation with common stock trading on The Nasdaq Capital Market under the ticker ICCC [S1].
  • As of March 24, 2026, ImmuCell had 9,046,799 shares outstanding [S1].
  • The company reported net income of $952,510 for the quarter ended September 30, 2026 [S2].
  • Basic and diluted earnings per share were $0.10 for the quarter ended September 30, 2026 [S2].
  • Cash and cash equivalents totaled $7,914,406 as of September 30, 2026 [S2].
  • Current assets were $21,577,479 and current liabilities were $4,680,612 as of September 30, 2026, resulting in a current ratio of 4.61 and a cash ratio of 1.9 [S2].
  • The company reported revenue of $6,444,880 for the quarter ended June 30, 2025 [S2].
  • ImmuCell's business includes product lines related to cattle health, including First Defense® and Tri-Shield products [N7][N4].
  • Recent quarterly sales showed growth: Q2 2026 sales were $7 million with a 20% rise for six-month sales in preliminary results [N4].
  • Q1 2026 earnings rose year-over-year with sales climbing on strong demand [N5].
  • The company reported narrowing net loss in 2025 with improved sales and margins [N8].
  • ImmuCell's Q2 2026 earnings call highlighted earnings and sales growth year-over-year, though the stock price fell 8.8% despite these improvements [N1][N2][N3].
  • The company has ongoing lease agreements and debt financing arrangements with various banks and institutions, including Gorham Savings Bank and Maine Community Bank [S1][S2].
  • Idle assets related to a manufacturing facility previously used for Re-Tain® are planned to be refitted for First Defense® production [S2].
  • The company has stock option and incentive plans approved and revised in 2025 [S1].
Sources
Sources - Context summary

Generated 2026-11-13

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-05-13 | 10-K/A
  • S2 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-08-27 | www.nasdaq.com | ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2 | https://www.nasdaq.com/articles/immucell-stock-falls-88-despite-y-y-earnings-sales-growth-q2
  • N2 | 2026-08-20 | www.nasdaq.com | ImmuCell (ICCC) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/immucell-iccc-q2-2026-earnings-call-transcript
  • N3 | 2026-08-14 | www.nasdaq.com | ImmuCell Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/immucell-q2-earnings-call-highlights
  • N4 | 2026-07-10 | www.nasdaq.com | ImmuCell Records Q2 Sales Of $7 Mln & 20% Rise For Six-Month Sales In Preliminary Results | https://www.nasdaq.com/articles/immucell-records-q2-sales-7-mln-20-rise-six-month-sales-preliminary-results
  • N5 | 2026-05-25 | www.nasdaq.com | ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand | https://www.nasdaq.com/articles/immucell-q1-earnings-rise-y-y-sales-climb-strong-demand
  • N6 | 2026-04-22 | www.nasdaq.com | The Zacks Analyst Blog The Goldman Sachs, NextEra, Shopify, Landmark and ImmuCell | https://www.nasdaq.com/articles/zacks-analyst-blog-goldman-sachs-nextera-shopify-landmark-and-immucell
  • N7 | 2026-04-09 | www.nasdaq.com | ImmuCell Corp Reports Q1 Preliminary Revenue Growth Above 25% Driven By Tri-Shield Sales | https://www.nasdaq.com/articles/immucell-corp-reports-q1-preliminary-revenue-growth-above-25-driven-tri-shield-sales
  • N8 | 2026-03-06 | www.nasdaq.com | ImmuCell 2025 Net Loss Narrows Y/Y as Sales & Margins Improve | https://www.nasdaq.com/articles/immucell-2025-net-loss-narrows-y-y-sales-margins-improve
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine